empagliflozin + DPP-4 inhibitors
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Nov 16, 2016 โ Mar 11, 2024
NCT ID
NCT03464045About empagliflozin + DPP-4 inhibitors
empagliflozin + DPP-4 inhibitors is a pre-clinical stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT03464045. Target conditions include Diabetes Mellitus, Type 2.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03464045 | Pre-clinical | Completed |
| NCT02864914 | Pre-clinical | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2